Ocular toxicity of intravitreal clarithromycin
- PMID: 10546942
- DOI: 10.1097/00006982-199909000-00013
Ocular toxicity of intravitreal clarithromycin
Abstract
Objective: To investigate the ocular toxicity and clearance of intravitreal clarithromycin lactobionate (Klaricid) and to determine the highest nontoxic dose.
Materials and methods: To evaluate toxicity, 24 New Zealand white rabbits were divided into six groups (four rabbits each). Rabbits were examined preoperatively and electroretinography (ERG) was performed. The left eyes of the animals served as controls and received intravitreal injection of 0.1 mL sterile water. Klaricid (0.1 mL) was injected into the midvitreous cavity of the right eyes at concentrations of 25 microg, 250 microg, 500 microg, 1.0 mg, 2.0 mg, and 4.0 mg/0.1 mL. The animals were followed up to 15 days postinjection by clinical examination and ERG. The animals were killed and the eyes were enucleated and processed for light microscopy. Ten New Zealand rabbits were used for the vitreous clearance study as drug test rabbits and two additional rabbits were used to generate control retina and vitreous. The highest nontoxic dose (1 mg) was injected into the vitreous and the concentration of clarithromycin in the vitreous was determined using high-performance liquid chromatography at various time intervals after injection.
Results: Cataract occurred after intravitreal doses of 2.0 and 4.0 mg. Electroretinography showed decreasing b-wave amplitude with both dark- and light-adapted stimulus in the 4.0-mg group; it was normal in other groups. Histopathologic sections showed localized retinal necrosis and disorganization with the 2.0 and 4.0 mg dosage. No histologic changes were found in the other groups. The half-life of intravitreal clarithromycin was found to be 2 hours. No metabolites of clarithromycin were observed in the vitreous samples.
Conclusion: Intravitreal clarithromycin lactobionate is nontoxic to rabbit eyes up to a dose of 1.0 mg. Because of its broad-spectrum antibiotic effect and appropriate half-life in the vitreous, it may be a good choice for intravitreal treatment of susceptible organisms.
Similar articles
-
Ocular toxicity of intravitreal tacrolimus.Ophthalmic Surg Lasers. 2002 Mar-Apr;33(2):140-4. Ophthalmic Surg Lasers. 2002. PMID: 11942546
-
Evaluation of vitreous clearance and potential retinal toxicity of intravitreal lornoxicam (xefo).J Ocul Pharmacol Ther. 2013 Sep;29(7):627-32. doi: 10.1089/jop.2012.0194. Epub 2013 Apr 4. J Ocul Pharmacol Ther. 2013. PMID: 23556534
-
Determination of nontoxic concentrations of piperacillin/tazobactam for intravitreal application. An electroretinographic, histopathologic and morphometric analysis.Ophthalmic Res. 2004 May-Jun;36(3):139-44. doi: 10.1159/000077326. Ophthalmic Res. 2004. PMID: 15103204
-
Safety of Intravitreal Injection of Stivant, a Biosimilar to Bevacizumab, in Rabbit Eyes.J Ophthalmic Vis Res. 2020 Aug 6;15(3):341-350. doi: 10.18502/jovr.v15i3.7453. eCollection 2020 Jul-Sep. J Ophthalmic Vis Res. 2020. PMID: 32864065 Free PMC article. Review.
-
Intravitreal nanoparticles for retinal delivery.Drug Discov Today. 2019 Aug;24(8):1510-1523. doi: 10.1016/j.drudis.2019.05.005. Epub 2019 May 16. Drug Discov Today. 2019. PMID: 31102730 Review.
Cited by
-
International Harmonization of Nomenclature and Diagnostic Criteria (INHAND): Nonproliferative and Proliferative Lesions of Nonrodent Ocular Tissues.Toxicol Pathol. 2024 Oct;52(7):368-455. doi: 10.1177/01926233241283708. Toxicol Pathol. 2024. PMID: 39658869 Free PMC article. Review.
-
Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR).Pharm Res. 2009 May;26(5):1236-60. doi: 10.1007/s11095-008-9728-7. Epub 2008 Oct 8. Pharm Res. 2009. PMID: 18841448
-
Pharmacokinetics of intravitreal antibiotics in endophthalmitis.J Ophthalmic Inflamm Infect. 2014 Sep 10;4:22. doi: 10.1186/s12348-014-0022-z. eCollection 2014. J Ophthalmic Inflamm Infect. 2014. PMID: 25667683 Free PMC article. Review.
-
Prediction of the vitreal half-life of small molecular drug-like compounds.Pharm Res. 2012 Dec;29(12):3302-11. doi: 10.1007/s11095-012-0822-5. Epub 2012 Jul 10. Pharm Res. 2012. PMID: 22777295
-
Retina-choroid-sclera permeability for ophthalmic drugs in the vitreous to blood direction: quantitative assessment.Pharm Res. 2013 Jan;30(1):41-59. doi: 10.1007/s11095-012-0847-9. Epub 2012 Oct 2. Pharm Res. 2013. PMID: 23054085
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical